Aptevo Therapeutics Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
Aptevo Therapeutics (APVO) Tops Q2 EPS by 3c
August 9, 2019 9:02 AM EDTAptevo Therapeutics (NASDAQ: APVO) reported Q2 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $7.36 million versus the consensus estimate of $7.04 million.
Second Quarter 2019 Highlights
Achieved 32% increase in year-over-year IXINITY net revenue in the first half of 2019 through continued expansion of the patient base for IXINITYLaunched a new, more desirable 3,000 IU assay for IXINITY providing advantages for Hemophilia B patients and our channel partnersCompleted dosing in a Phase 1 clinical trial of APVO210 designed to evaluate single ascending doses (SAD) in healthy... More